Biosimilar uptake has exceeded expectations for savings and access.

The United States lags other countries on biosimilar uptake.

The progress with biosimilar absorption has been satisfactory.

Progress with biosimilars has been uneven across drug categories.

from pharmacy benefit manager (PBM) Prime Therapeutics described ways of promoting biosimilar use and overcoming the barriers, such as pricing that gives reference products an edge and "variable" physician and patient awareness on safety and efficacy. However, in a case example from the PBM's own experience, Prime Therapeutics described high conversion rates to biosimilar versions of granulocyte-colony stimulating factor (G-CSF) biosimilars for the treatment of neutropenia, or a weakened immune system. 

Polls

News

With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization. 

Poll: How Much Progress With Biosimilars Has the United States Made?